Research News

New understandings of medication and withdrawal experiences warrant rethinking conceptualizations of health and “madness."

According to patient reports, SSRI antidepressants most frequently lead to the subjective experience of emotional blunting.

A new study conducted in the Netherlands, published in the Journal of Psychiatric Research, investigates the effect of terminating an unwanted pregnancy on the...

Two experts—a leading neuroscientist studying OCD, and a psychiatrist specializing in OCD treatment—question whether expensive brain imaging research has added anything to the treatment of OCD.

An article in JAMA Psychiatry advises very slow tapering for best results when discontinuing antipsychotic drugs.

A new study conducted by Jeffrey Vittengl at Truman University has found that taking antidepressant medications resulted in more severe depression symptoms after nine years.

The alternative treatment model of Soteria helps individuals suffering from schizophrenia without relying on medication or coercion.

The largest-ever meta-analysis of antidepressant trials appeared yesterday in the British Medical Journal. Researchers from the Cochrane Collaboration reviewed 70 trials (involving 18,526 subjects), to find that - counter to the initially-reported findings - antidepressants doubled the risk of suicide and aggression in subjects under 18. This risk had been misrepresented in the original study reports, the authors say, and suggest that the risks to adults may be similarly under-reported.

A new study explores effective forms of grief support, finding that animals are more effective than humans in providing support.

A new study explores how people manage to discontinue antipsychotic medication and examines how social supports may improve outcomes.

An analysis of last year’s positive finding in The Lancet about antidepressant efficacy shows errors, obfuscations, and misrepresentations.

A closer look at a new study reporting that the supplement D-cycloserine improved anxiety when used with exposure therapy.

In adolescent depression treatment, those who received a placebo but thought they received Prozac improved more than those who received the drug and knew it.

Selective publication bias in top psychiatry journals was not explained by the quality of the studies, but by financial ties to pharma.

Mothers’ loss of group membership impacts their social identity and linked to postpartum depression.

MIA's Peter Simons interviews David Cohen, PhD, on his path to researching mental health, coercive practices, and discontinuation from psychiatric drugs.

A new article in Lancet Psychiatry debunks past studies claiming that those on low doses of antipsychotics are more likely to relapse.

Researchers look at voice hearing experiences shared by nonclinical samples, exploring these experiences in the general population.

Researchers studied whether antipsychotics could prevent transition to full psychosis and found that the drugs worsened outcomes.

Dr. Yolande Lucire, a psychiatrist from Australia, recently published a paper about the iatrogenic effects of psychiatric drugs.

A new study to be published in the next issue of Schizophrenia Research examines patients suffering from a first-episode of psychosis who stop taking any antipsychotic drugs. The researchers attempt to identify variables that can serve as predictors of the successful discontinuation of antipsychotics. They find, for example, that those who discontinue the drugs have, on average, the same outcomes as those who stay on them, and that those who have better social integration are more likely to discontinue without relapse.

In a new study, researchers found that bright light therapy was an effective treatment for nonseasonal major depressive disorder (MDD) while Prozac (Fluoxetine) alone...

On Wednesday, JAMA Psychiatry released a meta-analysis comparing the results of cognitive-behavioral therapy and antidepressant medication in severely depressed populations. Currently, many practice guidelines suggest that antidepressants be used over psychotherapy for major depressive disorder. The analysis, however, found that “patients with more severe depression were no more likely to require medications to improve than patients with less severe depression.”

Those who did not get antipsychotics in the first month were almost twice as likely to be in recovery after five years.

The FDA collaborated with Biogen to conduct repeated re-analyses of aducanumab for Alzheimer's and FDA committee members are raising concerns.